Pharminent

J&J, Roche among companies selected for FDA digital health pilot

The regulator hopes to improve how it reviews digital medical devices, aiming to streamline the path to market for new health tools. http://www.healthcaredive.com/news/apple-fitbit-among-companies-selected-for-fda-digital-health-precertificat/505867/

Filed under: Company

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

The positive results in the clinical trial help validate Alnylam’s $7 billion market valuation and pave the way for more drugs based on RNAi technology. https://www.statnews.com/2017/09/20/alnylam-drug-success/

Filed under: Company

Bristol, Roche tap Halozyme for tech platform

Between upfront, milestone and royalty payments, the separate licensing agreements could be worth more than $2 billion combined. http://www.biopharmadive.com/news/bristol-roche-tap-halozyme-for-tech-platform/504958/

Filed under: Company

AstraZeneca ups investment in messenger RNA drugs with Ethris deal

FRANKFURT (Reuters) – AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros ($29 million) on a research alliance with German biotech start-up Ethris.

https://www.reuters.com/article/us-astrazeneca-ethris-idUSKCN1B10ZR

Filed under: Company

Amgen And Humana Partner For Improved Health Outcomes And Efficiency

THOUSAND OAKS, Calif. and LOUISVILLE, Ky., Aug. 17, 2017 /PRNewswire/ — Two of the nation’s leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to identify opportunities to improve health… http://www.prnewswire.com/news-releases/amgen-and-humana-partner-for-improved-health-outcomes-and-efficiency-300506215.html

Filed under: Company

Pfizer spinoff Zoetis ups 2017 guidance, eyes more M&A for future growth

What does Pfizer animal health spinoff Zoetis share with its former parent, aside from its lineage? They’re both under pressure from investors to drive growth through acquisitions. Zoetis met second-quarter expectations and brightened its forecast for the rest of the year, and now it’s looking to M&A to drive further growth. http://www.fiercepharma.com/financials/pfizer-spinoff-zoetis-ups-2017-guidance-eyes-m-a-for-future-growth

Filed under: Company

GSK looks to exit rare diseases

The British drugmaker is putting its rare disease business up for sale amid a company-wide refocusing. http://www.biopharmadive.com/news/glaxosmithkline-gsk-rare-disease-sell-divest-strimvelis/448087/

Filed under: Company

Lilly puts two-thirds of mid-phase cancer pipeline up for sale in major shake up of R&D priorities

Eli Lilly is seeking partners for two-thirds of its mid-phase oncology compounds. The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to mid-stage assets it thinks can become the new standard of care. http://www.fiercebiotech.com/biotech/lilly-puts-two-thirds-mid-phase-cancer-pipeline-up-for-sale-major-shake-up-r-d-priorities

Filed under: Company

Sanofi to Acquire Protein Sciences

NewsAcquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio.Contributed Author: SanofiTopics: Pharma Mergers & Acquistions https://www.dddmag.com/news/2017/07/sanofi-acquire-protein-sciences

Filed under: Company

Alnylam Buckles Down On A Belt Of Rare Diseases

https://seekingalpha.com/article/4087017-alnylam-buckles-belt-rare-diseases

Filed under: Company

Pfizer To Lose Exclusivity Of Key Brands

https://seekingalpha.com/article/4082947-pfizer-lose-exclusivity-key-brands

Filed under: Company

J&J Innovation Reveals New Collaborations in NASH, Diabetes, and Rheumatoid Arthritis

NewsThese new deals will also help advance cutting-edge technologies, including 3-D printing to create customized health solutions.Contributed Author: J&J InnovationTopics: Biotech https://www.dddmag.com/news/2017/06/j-j-innovation-reveals-new-collaborations-nash-diabetes-and-rheumatoid-arthritis

Filed under: Company

Sanofi to invest further in biologics

PARIS (Reuters) – Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential.

http://www.reuters.com/article/us-sanofi-biologics-idUSKBN1951IV

Filed under: Company

Continuous Manufacturing: Novartis’ experiment in the future of drug production

Continuous manufacturing has long been touted as the future of drug production. Pharmafile approached Novartis for more details about its successes in the area, and the challenges, of developed the new process.
Why did Novartis decide to take the step to experiment in continuous manufacturing processes? 
read more http://www.pharmafile.com/news/514335/continuous-manufacturing-novartis-experiment-future-drug-production

Filed under: Company

AstraZeneca offloads more non-core assets

The British drugmaker has worked to trim its portfolio, selling off older drugs to help offset revenue declines from key products. http://www.biopharmadive.com/news/astrazeneca-offloads-more-non-core-assets/443315/

Filed under: Company

Pfizer taps Sangamo for hemophilia gene therapy

The deal validates Sangamo’s gene therapy technology and provides Pfizer with another gene therapy in the hemophilia space.  http://www.biopharmadive.com/news/pfizer-sangamo-hemophilia-gene-therapy/442527/

Filed under: Company

Novartis exercises option with Conatus for NASH treatment

Novartis has exercised its option with ConatusPharmaceuticals for an exclusive license for the worldwide development and commercialization of emricasan, a potential treatment for non-alcoholic steatohepatitis (NASH). http://drugdiscovery.pharmaceutical-business-review.com/news/novartis-exercises-option-to-develop-conatus-emricasan-to-treat-nash-050517-5805546

Filed under: Company

Cambridge’s bluebird bio licenses delivery tech to Novartis, GSK

http://www.bizjournals.com/boston/news/2017/05/02/cambridges-bluebird-bio-licenses-delivery-tech-to.html

Filed under: Company

Novartis looks earlier as biotech gets too expensive

The Swiss pharma is having trouble finding assets it likes to flesh out its pipeline as biotech valuations grow and its own earnings stay flat.  http://www.biopharmadive.com/news/novartis-looks-earlier-as-biotech-gets-too-expensive/441204/

Filed under: Company

Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration

DUBLIN, April 18, 2017 /PRNewswire/ — Allergan, a leading global biopharmaceutical company, announced today that it has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan’s cenicriviroc (CVC) and Novartis’ lead FXR agonist for the treatment o… http://www.prnewswire.com/news-releases/allergan-expands-leading-research–development-nash-program-with-novartis-clinical-collaboration-300440168.html

Filed under: Company

Categories